NASDAQ: AXDX |
| Healthcare / Medical Diagnostics & Research / USA |
1.36 | +0.2000 | +17.24% | Vol 6.19M | 1Y Perf -86.29% |
Jun 24th, 2022 16:00 DELAYED |
BID | 1.36 | ASK | 1.47 | ||
Open | 1.15 | Previous Close | 1.16 | ||
Pre-Market | - | After-Market | 1.43 | ||
- - | 0.07 5.15% |
Target Price | 5.00 | Analyst Rating | Hold 3.00 | |
Potential % | 267.65 | Finscreener Ranking | ★★★★ 53.49 | |
Insiders Trans % 3/6/12 mo. | -100/50/78 | Value Ranking | ★★ 46.03 | |
Insiders Value % 3/6/12 mo. | -100/88/98 | Growth Ranking | ★★★★ 60.59 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/57/93 | Income Ranking | — - | |
Price Range Ratio 52W % | 9.77 | Earnings Rating | Strong Buy | |
Market Cap | 108.03M | Earnings Date | 4th Aug 2022 | |
Alpha | -0.06 | Standard Deviation | 0.22 | |
Beta | 1.92 |
Today's Price Range 1.111.54 | 52W Range 0.50209.28 | 5 Year PE Ratio Range -13.00-11.10 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | 56.32% | ||
1 Month | 147.90% | ||
3 Months | -7.48% | ||
6 Months | -73.49% | ||
1 Year | -86.29% | ||
3 Years | -93.14% | ||
5 Years | -95.50% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -188.76 | |||
ROE last 12 Months | 109.87 | |||
ROA (5Y Avg) | -58.94 | |||
ROA last 12 Months | -82.99 | |||
ROC (5Y Avg) | -52.91 | |||
ROC last 12 Months | -51.28 | |||
Return on invested Capital Q | -13.54 | |||
Return on invested Capital Y | -47.85 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 2.30 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-0.80 | ||||
89.93 | ||||
5.65 | ||||
213.80 | ||||
-1.50 | ||||
-0.68 | ||||
-1.22 | ||||
-0.71 | ||||
137.71M | ||||
Forward PE | -0.66 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
6.40 | ||||
7.40 | ||||
0.93 | ||||
12.85 | ||||
-4.50 | ||||
Leverage Ratio | -1.60 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-3.90 | ||||
-451.90 | ||||
-431.60 | ||||
-1 072.90 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
12.22M | ||||
0.15 | ||||
17.79 | ||||
56.68 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | -0.32 | -0.25 | 21.88 |
Q04 2021 | -0.30 | -0.23 | 23.33 |
Q03 2021 | -0.35 | -0.15 | 57.14 |
Q02 2021 | -0.35 | -0.36 | -2.86 |
Q01 2021 | -0.33 | -0.41 | -24.24 |
Q04 2020 | -0.31 | -0.33 | -6.45 |
Q03 2020 | -0.33 | -0.33 | 0.00 |
Q02 2020 | -0.34 | -0.35 | -2.94 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -0.33 | 0.00 | - |
9/2022 QR | -0.34 | 0.00 | - |
12/2022 FY | -1.33 | 0.00 | - |
12/2023 FY | -1.36 | 0.00 | - |
Next Report Date | 4th Aug 2022 |
Estimated EPS Next Report | -0.33 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 6.19M |
Shares Outstanding | 79.44K |
Shares Float | 51.28M |
Trades Count | 7.00K |
Dollar Volume | 8.42M |
Avg. Volume | 1.48M |
Avg. Weekly Volume | 1.52M |
Avg. Monthly Volume | 1.88M |
Avg. Quarterly Volume | 1.05M |
Accelerate Diagnostics Inc. (NASDAQ: AXDX) stock closed at 1.36 per share at the end of the most recent trading day (a 17.24% change compared to the prior day closing price) with a volume of 6.19M shares and market capitalization of 108.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 275 people. Accelerate Diagnostics Inc. CEO is John Phillips.
The one-year performance of Accelerate Diagnostics Inc. stock is -86.29%, while year-to-date (YTD) performance is -73.95%. AXDX stock has a five-year performance of -95.5%. Its 52-week range is between 0.502 and 9.28, which gives AXDX stock a 52-week price range ratio of 9.77%
Accelerate Diagnostics Inc. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 89.93, a price-to-sale (PS) ratio of 5.65, a price to cashflow ratio of 213.80, a PEG ratio of 2.32, a ROA of -82.99%, a ROC of -51.28% and a ROE of 109.87%. The company’s profit margin is -%, its EBITDA margin is -431.60%, and its revenue ttm is $12.22 Million , which makes it $0.15 revenue per share.
Of the last four earnings reports from Accelerate Diagnostics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.33 for the next earnings report. Accelerate Diagnostics Inc.’s next earnings report date is 04th Aug 2022.
The consensus rating of Wall Street analysts for Accelerate Diagnostics Inc. is Hold (3), with a target price of $5, which is +267.65% compared to the current price. The earnings rating for Accelerate Diagnostics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Accelerate Diagnostics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Accelerate Diagnostics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.07, ATR14 : 0.18, CCI20 : 206.10, Chaikin Money Flow : 0.19, MACD : 0.09, Money Flow Index : 84.80, ROC : 18.26, RSI : 70.70, STOCH (14,3) : 81.25, STOCH RSI : 1.00, UO : 64.60, Williams %R : -18.75), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Accelerate Diagnostics Inc. in the last 12-months were: Hany Massarany (Buy at a value of $119 000), Jack Phillips (Option Excercise at a value of $0), Jack Phillips (Sold 115 559 shares of value $119 603 ), Jack W Schuler (Buy at a value of $10 470 125), Jack W. Schuler (Buy at a value of $10 470 125), Ron Price (Option Excercise at a value of $0), Ron Price (Sold 15 072 shares of value $14 771 ), Steven Reichling (Option Excercise at a value of $0), Steven Reichling (Sold 29 915 shares of value $29 317 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Hold | Hold | Hold |
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques.
CEO: John Phillips
Telephone: +1 520 365-3100
Address: 3950 South Country Club Road, Tucson 85714, AZ, US
Number of employees: 275
Sat, 19 Mar 2022 09:11 GMT Accelerate Diagnostics (AXDX) Gets a Hold Rating from BTIG
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.